Cell and gene therapies are transforming the way certain fatal illnesses are cured, managed and treated. One such example, is CAR-T therapy which is a form of cancer treatment that uses a chimeric antigen receptor (CAR) to target killer T-cells towards tumour cells in the body. The first marketed CAR-T therapies, Kymriah and Yescarta, have been able to cure over 60% of previously hopeless leukaemia cases. However, the method currently requires therapeutic cells to be modified and grown outside the body, which is a highly complex and expensive process. The production process results in cells of variable quality, and treatments priced over several £100,000s. In addition, these therapies currently only work well in blood cancers (less than 4% of total cases), and more effective cell products are needed to make an impact on other tumours. ImmTune Therapies is on a mission to revolutionise the way these therapies are manufactured so that they are affordable, and therefore can be accessed by a wider patient population. Our technology is based on proprietary non-viral vectors that can deliver cargoes directly to cells of choice inside the patient's body. This in-body generation of therapeutically active cells is cheaper, and produces more effective and longer-lasting curative products. This allows ImmTune to platform and empower the revolutionary cancer medicines of tomorrow. We are building a platform which would allow us to use our technology well beyond blood cancer, and provide an affordable option for other disease indications including solid tumours, autoimmune and infectious diseases.